Atrial fibrillation and stroke;Vorhofflimmern und hirninfarkt

Therapeutische Umschau

Volumn 60, Issue 9, 2003, Pages 527-534

  Mattle, Heinrich P ^a   Schwerzmann, M ^a   Seiler, Ch ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; WARFARIN;

AGE; ANTICOAGULATION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; DIABETES MELLITUS; DRUG EFFICACY; EASTERN EUROPE; EMBOLISM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART FUNCTION; HEART LEFT ATRIUM; HEART RATE; HEMODYNAMICS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; PREVALENCE; RECURRENT DISEASE; REVIEW; STROKE; SWITZERLAND; SYSTEMIC CIRCULATION; SYSTOLE; THROMBOGENESIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT INDICATION; VALVULAR HEART DISEASE;

EID: 0141829810     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.60.9.527     Document Type: Review

References (35)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke. The Framingham Study. Stroke 1991; 22: 983-8.
2. Hart RG, Halperin JL. Atrial fibrillation and stroke. Concepts and controversies. Stroke 2001; 32: 803-8.
3. Agmon Y, Khandheria BK, Meissner I, Schwartz GL, Petterson TM, O'Fallon WM, Gentile F, Spittell PC, Whisnant JP, Wiebers DO, Covalt JL, Seward JB. Association of atrial fibrillation and aortic atherosclerosis: a population-based study. Mayo Clin Proc 2001; 76: 252-9.
4. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5.
5. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995; 155: 469-73.
6. International Stroke Trial Collaborative Group: The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both or neither among 19 435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-81.
7. Saxena R, Lewis S, Berge E, Sandercock PAG, Koudstaal PJ, for the International Stroke Trial Collaborative Group: Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke 2001; 32: 2333-7.
8. Shively BK, Gelgand EA, Crawford MH. Regional left atrial stasis during atrial fibrillation and flutter: determinants and relation to stroke. J Am Coll Cardiol 1996 27: 1722-9.
9. Agmon Y, Khandheria BK, Gentile F, Seward JB. Echocardiographic assessment of the left atrial appendage. J Am Coll Cardiol 1999; 34: 1867-77.
10. Asinger RW, Koehler J, Pearce LA, Zabalgoitia M, Blackshear JL, Fenster PE, Strauss R, Hess D, Pennock GD, Rothbart RM, Halperin JL. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: II. Dense spontaneous echocardiographic contrast (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr 1999; 12: 1088-96.
11. Goldman ME, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Safford R, Halperin JL. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: reduced flow velocity in the left atrial appendage. J Am Soc Echocardiogr 1999; 12: 1080-7.
12. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death. The Framingham Heart Study. Circulation; 1998; 98: 946-52.
13. Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57.
14. Atrial Fibrillation Investigators: Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1,066 patients from three clinical trials. Arch Intern Med 1998; 158: 1316-20.
15. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW on behalf of the Stroke Prevention in Atrial Fibrillation (SPAF) Investigators: Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials: Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 1999; 30: 1223-9.
16. Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography: Transoesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med 1998; 128: 639-47.
17. EAFT (European Atrial Fibrillation Trial) Study Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-62.
18. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 2001; 119: 194S-206S.
19. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501.
20. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335: 540-6.
21. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1993; 118: 511-20.
22. Gorter JW et al for Stroke Prevention in Reversible Ischemia Trial (SPIRIT) and European Atrial Fibrillation (EAFT) study groups. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Neurology 1999; 53: 1319-27.
23. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333: 5-10.
24. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333:11-7
25. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC Jr, Klein WW, Alonso-Garcia A, Blomstrom-Lundqvist C, de Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A. American College of Cardiology/American Heart Association Task Force on Practice Guidelines.; European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation).; North American Society of Pacing and Electrophysiology. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation 2001; 104: 2118-50.
26. Hohnloser SH, Kuck K-H, Lilienthal J, for the PIAF Investigators: Rhythm or rate control in atrial fibrillation Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356: 1789-94.
27. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-33.
28. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJM, Tijssen JGP, Crijns HJGM, for the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group: A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-40.
29. Hart RG, Palacio S, Pearce LA. Atrial fibrillation, stroke, and acute antithrombotic therapy. Analysis of randomized clinical trials. Stroke 2002; 33: 2722-27.
30. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study II. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
31. The Clopidogrel in Unstable angina to prevent Recurrent Events trial investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
32. Steinhubl SR, Berger PB, Mann JT III, Fry ETA, DeLago A, Wilmer C, Topol EJ, for the CREDO Investigators: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. JAMA 2002; 288: 2411-20.
33. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KKL, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339: 1665-71.
34. SPORTIF III. Präsentiert an der European Stroke Conference, Valencia, 24. Mai 2003.
35. Sievert H, Lesh MD, Trepels T, Omran H, Bartorelli A, Bella PD, Nakai T, Reisman M, DiMario C, Block P, Kramer P, Fleschenberg D, Krumsdorf U, Scherer D. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation. Circulation 2002; 105: 1887-89.